WO2024171082 - STABLE PROTEIN COMPOSITIONS OF ANTI-PD1 ANTIBODY
National phase entry:
Publication Number
WO/2024/171082
Publication Date
22.08.2024
International Application No.
PCT/IB2024/051388
International Filing Date
14.02.2024
Title **
[English]
STABLE PROTEIN COMPOSITIONS OF ANTI-PD1 ANTIBODY
[French]
COMPOSITIONS DE PROTÉINES STABLES D'ANTICORPS ANTI-PD1
Applicants **
SUN PHARMACEUTICAL INDUSTRIES LIMITED
Sun House, Plot No. 201 B/1,
Western Express Highway,
Goregaon (E)
Mumbai, Maharashtra 400 063, IN
Inventors
SHAH, Bhavik Kumar
Sun Pharmaceutical Industries Limited
Nima Compound, Near Pratham Enclave, Tandalja
Vadodara, Gujarat 390012, IN
SHARMA, Manish
Sun Pharmaceutical Industries Limited
Nima Compound, Near Pratham Enclave, Tandalja
Vadodara, Gujarat 390012, IN
JOGANI, Viralkumar Vinodlal
Sun Pharmaceutical Industries Limited
Nima Compound, Near Pratham Enclave, Tandalja
Vadodara, Gujarat 390012, IN
KHOPADE, Ajay Jaysingh
Sun Pharmaceutical Industries Limited
Nima Compound, Near Pratham Enclave, Tandalja
Vadodara, Gujarat 390012, IN
NAGARAJA, Ravishankara Madavati
Nima Compound, Near Pratham Enclave, Tandalja
Vadodara, Gujarat 390012, IN
CHOUHAN, Pankaj Singh
Sun Pharmaceutical Industries Limited
Nima Compound, Near Pratham Enclave, Tandalja
Vadodara, Gujarat 390012, IN
Priority Data
202321010367
16.02.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1706 | |
| EPO | Filing, Examination | 11351 | |
| Japan | Filing | 592 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 13835 |
Total: 28059 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to stable compositions of an antibody against human programmed death receptor PD-1, or antigen binding fragments thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. The present invention relates to pharmaceutical compositions of an anti-PD1 antibody comprising a buffer, a sugar or sugar alcohol and a surfactant. In some embodiments of the invention, the formulations may be administered to a subject by intravenous or subcutaneous administration.[French]
L'invention concerne des compositions stables d'un anticorps dirigé contre le récepteur de mort programmée humaine PD-1, ou des fragments de liaison à l'antigène de celui-ci. L'invention concerne en outre des procédés de traitement de divers cancers avec des formulations stables de l'invention. La présente invention concerne des compositions pharmaceutiques d'un anticorps anti-PD1 comprenant un tampon, un sucre ou un alcool de sucre et un tensioactif. Dans certains modes de réalisation de l'invention, les formulations peuvent être administrées à un sujet par administration intraveineuse ou sous-cutanée.